0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters to the Editor |

Antidepressant Effects of Repetitive Transcranial Magnetic Stimulation in the Elderly: Correlation Between Effect Size and Coil-Cortex Distance

Scot E Purdon, PhD
Arch Gen Psychiatry. 2002;59(6):573-575. doi:.
Text Size: A A A
Published online

Extract

In reply

Dr Sharma's criticism of the neuropsychological comparison of olanzapine, risperidone, and haloperidol1 accurately suggests that the dose of the treatments may be relevant to the results. A recent demonstration of the value of relatively low-dose risperidone in the alleviation of psychotic symptoms in patients with early phase schizophrenia who were treated for more than 1 year2 provides the first direct empirical support for the comments of Dr Sharma regarding the potential value of similarly low doses of risperidone in treating the cognitive deficits associated with schizophrenia. As Dr Sharma acknowledged, my colleagues and I advised caution in generalization beyond the particular sample and dose ranges examined in our study, and we speculated on the importance of further studies with risperidone, given a perceived trend toward the use of lower doses in clinical practice. Although a stratification analysis failed to detect cognitive improvement from risperidone in the low-dose conditions, and we did not detect additional cognitive improvement in the risperidone subsample not receiving anticholinergic supplements, it is possible that larger-sample investigations with greater power to detect smaller effect sizes and a broader dose range for risperidone may produce results different from the reported findings. However, Dr Sharma's characterization of our dose range as "aberrant" or "unrealistic" seems to be overzealous. Prior to the recently published low-dose study,2 the assumption of value from low-dose risperidone was based on anecdotal reports from clinicians, whereas an optimal dose range of 4 mg to 10 mg per day was advised in the product monograph and supported by a large-sample study that had used a flexible dose strategy3 and by a naturalistic survey of 2657 patients in Spain.4 Moreover, the actual dose of risperidone used in our study1 was flexible within the range of 4 mg to 10 mg per day, and the clinician responsible for the care of each patient determined the dose deemed necessary for symptom management. The discrepancy between the daily dose required in the low-dose study2 and that of our study could relate to a variety of patient-specific or clinician-specific features. For example, the low-dose report indicated that 25% of the patients assigned to risperidone had their regimens discontinued and were assigned to treatment with clozapine or a depot first-generation neuroleptic, perhaps relating to difficulties in sustaining the low-dose strategy in a subsample of patients. Additional data are required to confirm the general value of the low-dose strategy to patients with schizophrenia and to evaluate the possibility of a greater cognitive change with a lower dose of risperidone.

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();